Abbonarsi

Endoscopic powered resection device for residual colonic lesions: the first multicenter, prospective, international clinical study - 20/04/24

Doi : 10.1016/j.gie.2023.11.050 
Mate Knabe, MD, PhD 1, ⁎ , Roberta Maselli, PhD 2, Elodie Cesbron-Metivier, MD 3, Stephan Hollerbach, MD 4, Lucio Petruzziello, MD 5, Frédéric Prat, MD 6, Harshit S. Khara, MD 7, Mathieu Pioche, MD, PhD 8, Dirk Hartmann, MD 9, Paola Cesaro, MD 10, Federico Barbaro, MD, PhD 5, Arthur Berger, MD, PhD 11, Cristiano Spada, MD, PhD 10, 5, David L. Diehl, MD 7, Andrea May, MD 12, Thierry Ponchon, MD 8, Alessandro Repici, MD 2, Guido Costamagna, MD 5
1 Centrum Gastroenterology Bethanien (CGB), Bethanien Hospital Frankfurt, Germany 
2 Division of Gastroenterology and Digestive Endoscopy, Department of Gastroenterology Humanitas Research Hospital, Milano, Italy 
3 Service d’hépato-gastro-entérologie, CHU Angers, Angers, France 
4 Department of Gastroenterology, Allgemeines Krankenhaus Celle, Celle, Germany 
5 Digestive Endoscopy Unit, Università Cattolica del Sacro Cuore, Rome, Italy, Digestive Endoscopy Unit, Fondazione Policlinico Universitario A. Gemelli IRCSS, Rome, Italia 
6 Endoscopy Unit, Beaujon Hospital, Publique des Hôpitaux de Paris, Clichy, France 
7 Department of Gastroenterology and Hepatology, Geisinger Medical Center, Danville, Pennsylvania, USA 
8 Endoscopy and Gastroenterology Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France 
9 Department of General Internal Medicine, Diabetology, Gastroenterology and Oncology, Katholisches Klinikum Mainz, Mainz, Germany 
10 Digestive Endoscopy Unit and Gastroenterology, Fondazione Poliambulanza, Brescia, Italy 
11 CHU Bordeaux, Department of Gastroenterology and Digestive Endoscopy, Univ. Bordeaux, Bordeaux, France 
12 Department of Gastroenterology, Oncology and Pneumology, Asklepios Paulinen Klinik, Wiesbaden, Germany 

∗Reprint requests: Mate Knabe, PhD, MD, Medizinische Klinik I, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 636069 Frankfurt, Germany.Medizinische Klinik IUniversitätsklinikum FrankfurtTheodor-Stern-Kai 7Frankfurt636069Germany

Abstract

Background and Aims

Endoscopic resection is standard treatment for adenomatous colorectal lesions. Depending on lesion morphology and resection technique, recurrence can occur. Scarred adenomas are challenging to resect and may require surgical management. This study evaluated the safety and effectiveness of an endoscopic powered resection (EPR) system for scarred adenomatous colorectal lesions.

Methods

This single-arm, prospective, multicenter study was conducted from January 2018 to January 2021 at 12 sites. Patients with persistent flat or sessile colorectal lesions were enrolled. Primary end points were technical success (the ability of the device to resect the lesion[s] without use of other resection devices without device-related serious adverse events [AEs]) and safety (the occurrence of AEs through 90 days). Secondary end points included endoscopic confirmation of resection completeness, occurrence of colon stenosis, disease persistence, and diagnostic value of resected specimens.

Results

Sixty-five patients were in the intention-to-treat/safety analysis population. Primary analysis was performed on 45 per-protocol (PP) patients with 48 lesions. All PP patients were solely treated by using the EPR device. Technical success was achieved in 44 (98%) patients. Three (5%) serious AEs occurred: 2 delayed self-limited bleeds and 1 perforation. Nonserious AEs included 4 (6%) cases of mild intraprocedural bleeding. Completeness of resection and histopathologic diagnosis of tissue specimens were achieved in all patients. Twenty-one (46.7%) patients had disease persistence after the first treatment, and there was no colon stenosis.

Conclusions

EPR is safe and effective for benign, persistent, large (>20 mm), scarred colorectal adenomas and should be considered as an alternative treatment in lieu of surgery. A persistence rate of 46.7% indicates that >1 treatment is necessary for effective endoscopic treatment. (Clinical trial registration number: NCT04203667.)

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : AE, EPR, ESD, FTRD, ITT, PP, SAE


Mappa


© 2024  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 99 - N° 5

P. 778-786 - maggio 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • Deep learning–based lesion detection and severity grading of small-bowel Crohn’s disease ulcers on double-balloon endoscopy images
  • Wanqing Xie, Jing Hu, Pengcheng Liang, Qiao Mei, Aodi Wang, Qiuyuan Liu, Xiaofeng Liu, Juan Wu, Xiaodong Yang, Nannan Zhu, Bingqing Bai, Yiqing Mei, Zhen Liang, Wei Han, Mingmei Cheng
| Articolo seguente Articolo seguente
  • Endoscopist adenomas-per-colonoscopy detection rates and risk for postcolonoscopy colorectal cancer: data from the New Hampshire Colonoscopy Registry
  • Joseph C. Anderson, Douglas K. Rex, Todd A. Mackenzie, William Hisey, Christina M. Robinson, Lynn F. Butterly

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.